The Pharmaceutical Coronavirus Vaccine Johnson & Johnson showed promising results in first phase 1-2a clinical trials, something that could provide a significant boost to vaccination efforts around the world.
In the study, published in the New England Journal of Medicine it is revealed that the vaccine produced a neutralizing antibody immune response in more than 800 people, within two months of inoculation, in a younger population and in people older than 65 years.
Currently, efforts to distribute the two approved vaccines from Pfizer and Moderna have run into some logistical problems, in part because by using the messenger RNA technology require a extreme cooling, and people should receive two doses to achieve immunity. In the case of Johnson & Johnson, it is a single vaccine, which would also be more resistant because it is based on DNA technology.
Specifically, the latest results of the fase 1-2a de Johnson & Johnson they involved 805 participants in two groups, one with people from 18 to 55 years old and the other 65 years or older. More than 90% of the participants presented a immune response in a month, and all had levels of neutralizing antibodies day 57.
The results also showed a safety profile similar to that of existing vaccines, as indicated by the company on its site. The fever was the most frequent adverse response, as well as fatigue, headache, and body aches.
The positive is that the results also showed that a second dose of the vaccine more than doubled the amount of neutralizing antibodies, so it would not be uncommon for once released, this possibility could be considered. Such a dilemma will be resolved in the results of the clinical trials of step 3, that involved 45 thousand participants and they are expected by the end of January.
Recall that Johnson & Johnson briefly paused its testing in October after a volunteer developed an unexplained neurological disease. A subsequent security investigation determined that the disease was not related to the vaccine.